| MeSH term | MeSH ID | Detail |
|---|---|---|
| Burkitt Lymphoma | D002051 | 15 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Candidiasis, Vulvovaginal | D002181 | 8 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Cardiomyopathy, Hypertrophic | D002312 | 6 associated lipids |
| Cardiomyopathy, Restrictive | D002313 | 1 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Carpal Tunnel Syndrome | D002349 | 3 associated lipids |
| Catalepsy | D002375 | 30 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gaballa S et al. | Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. | 2016 | Cancer | pmid:27404668 |
| Jonas S et al. | De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. | 1997 | Cancer | pmid:9305716 |
| Gupta A et al. | Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. | 2006 | Cancer Chemother. Pharmacol. | pmid:16404634 |
| Naito M et al. | Reversal of multidrug resistance by an immunosuppressive agent FK-506. | 1992 | Cancer Chemother. Pharmacol. | pmid:1370765 |
| Holmes JA and Twentyman PR | The activity of deoxyspergualin in multidrug-resistant cells. | 1995 | Cancer Chemother. Pharmacol. | pmid:7554042 |
| Yamashita T et al. | Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation. | 2016 | Cancer Chemother. Pharmacol. | pmid:27217047 |
| Pawarode A et al. | Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. | 2007 | Cancer Chemother. Pharmacol. | pmid:17031644 |
| Song W et al. | Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. | 2008 | Cancer Gene Ther. | pmid:18566614 |
| Yoshizawa K et al. | Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t(2;3)(p11;q27) from a liver transplant patient. | 1993 | Cancer Genet. Cytogenet. | pmid:7506636 |
| Hodi FS et al. | Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. | 2005 | Cancer Immun. | pmid:15901138 |
| Yamamoto S et al. | Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. | 1994 | Cancer Lett. | pmid:7520353 |
| Datta D et al. | Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. | 2009 | Cancer Res. | pmid:19903851 |
| Matsumoto K et al. | mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. | 2009 | Cancer Res. | pmid:19738050 |
| Krishnamurthy S et al. | Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. | 2010 | Cancer Res. | pmid:21098716 |
| Paulmurugan R et al. | Molecular imaging of drug-modulated protein-protein interactions in living subjects. | 2004 | Cancer Res. | pmid:15026351 |
| Dilling MB et al. | Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. | 1994 | Cancer Res. | pmid:7508822 |
| Scheffold C et al. | Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. | 2002 | Cancer Res. | pmid:12384539 |
| Wandel C et al. | P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. | 1999 | Cancer Res. | pmid:10463589 |
| Aikawa Y et al. | Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells. | 2015 | Cancer Sci. | pmid:25529853 |
| Spain L et al. | Management of toxicities of immune checkpoint inhibitors. | 2016 | Cancer Treat. Rev. | pmid:26874776 |
| Radu CD et al. | Cotton-made cellulose support for anti-allergic pajamas. | 2013 | Carbohydr Polym | pmid:23618296 |
| Jiang H et al. | Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. | 1993 | Carcinogenesis | pmid:7678785 |
| Hunt SA | New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus. | 2000 May-Jun | Cardiol Rev | pmid:11174892 |
| Ekman-Joelsson BM et al. | Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. | 2017 | Cardiol Young | pmid:28780922 |
| Schrepfer S et al. | Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides? | 2007 | Cardiology | pmid:17028423 |
| Minamino T et al. | Chronic treatment with FK506 increases p70 S6 kinase activity associated with reduced nitric oxide synthase activity in rabbit hearts. | 2000 | Cardiovasc Drugs Ther | pmid:10935155 |
| Cai Q et al. | Reduction of infarct size in isolated rat heart by CsA and FK506: possible role of phosphatase inhibition. | 1998 | Cardiovasc Drugs Ther | pmid:9926283 |
| Seino Y et al. | Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. | 2003 | Cardiovasc Drugs Ther | pmid:12975596 |
| Radeleff B et al. | Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model. | 2008 Sep-Oct | Cardiovasc Intervent Radiol | pmid:18095019 |
| Waksman R et al. | Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. | 2007 Oct-Dec | Cardiovasc Revasc Med | pmid:18053948 |
| Bogossian H et al. | Expression of NO Synthase Under Medication with Cyclosporine A, Mycophenolate Mofetil, and Tacrolimus during Development of Transplant Vasculopathy on Rat Cardiac Allograft. | 2016 | Cardiovasc Ther | pmid:26924260 |
| Rezai N et al. | Effects of granulocyte-colony stimulating factor on bone marrow-derived progenitor cells in murine cardiac transplantation. | 2010 Jan-Feb | Cardiovasc. Pathol. | pmid:19144547 |
| Gajjar NA et al. | FK506 vs. cyclosporin. Pathologic findings in 1067 endomyocardial biopsies. | 2003 Mar-Apr | Cardiovasc. Pathol. | pmid:12684161 |
| Nakayama Y et al. | Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506. | 2003 Apr-Jun | Cardiovasc. Radiat. Med. | pmid:14581087 |
| Giordano A et al. | FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. | 2008 | Cardiovasc. Res. | pmid:18349138 |
| Obayashi M et al. | Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. | 2006 | Cardiovasc. Res. | pmid:16112660 |
| Yamamoto K et al. | Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. | 2002 | Cardiovasc. Res. | pmid:12062710 |
| Fauconnier J et al. | Ca2+-dependent reduction of IK1 in rat ventricular cells: a novel paradigm for arrhythmia in heart failure? | 2005 | Cardiovasc. Res. | pmid:16083867 |
| Zhang W | Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. | 2002 | Cardiovasc. Res. | pmid:11827679 |
| Zhao YT et al. | Sensitized signalling between L-type Ca2+ channels and ryanodine receptors in the absence or inhibition of FKBP12.6 in cardiomyocytes. | 2017 | Cardiovasc. Res. | pmid:28077437 |
| Weinbrenner C et al. | Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. | 1998 | Cardiovasc. Res. | pmid:9747435 |
| Wu Y and Anderson ME | Reduced repolarization reserve in ventricular myocytes from female mice. | 2002 | Cardiovasc. Res. | pmid:11861046 |
| Ono K et al. | Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca(2+) release in heart failure. | 2000 | Cardiovasc. Res. | pmid:11054478 |
| Ono M et al. | Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca(2+) release in heart failure. | 2010 | Cardiovasc. Res. | pmid:20388639 |
| Barilli A et al. | In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. | 2008 | Cardiovasc. Res. | pmid:18250144 |
| Bueno OF et al. | Calcineurin and hypertrophic heart disease: novel insights and remaining questions. | 2002 | Cardiovasc. Res. | pmid:11922891 |
| Feng X et al. | Protective effect of FK506 on myocardial ischemia/reperfusion injury by suppression of CaN and ASK1 signaling circuitry. | 2011 | Cardiovasc. Toxicol. | pmid:21076890 |
| Matl I | [Newer immunosuppressive agents and their place in current practice]. | 2000 | Cas. Lek. Cesk. | pmid:22666925 |
| Jung JH et al. | Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft. | 2006 | Catheter Cardiovasc Interv | pmid:16969853 |
| Berg R et al. | Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. | 2007 | Catheter Cardiovasc Interv | pmid:17932889 |
| Wieneke H et al. | Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. | 2003 | Catheter Cardiovasc Interv | pmid:14571494 |
| Schwartz RS | Beauty's only skin deep: surface technologies emerge in stenting. | 2003 | Catheter Cardiovasc Interv | pmid:14571495 |
| Ikeno F et al. | Novel percutaneous adventitial drug delivery system for regional vascular treatment. | 2004 | Catheter Cardiovasc Interv | pmid:15390346 |
| Hehrlein C | Dual drug release from stents-will we be happy with thing one and thing two? | 2007 | Catheter Cardiovasc Interv | pmid:18022914 |
| Kollum M et al. | Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. | 2005 | Catheter Cardiovasc Interv | pmid:15619311 |
| Tamburino C et al. | Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. | 2009 | Catheter Cardiovasc Interv | pmid:19156896 |
| Kornowski R | A critical appraisal of the Janus carbostent. | 2009 | Catheter Cardiovasc Interv | pmid:19156897 |
| Klein AJ and Brilakis ES | Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry. | 2012 | Catheter Cardiovasc Interv | pmid:22933349 |
| Cassese S et al. | Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study. | 2012 | Catheter Cardiovasc Interv | pmid:21735531 |
| Brillantes AB et al. | Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. | 1994 | Cell | pmid:7514503 |
| Jayachandran R et al. | Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. | 2007 | Cell | pmid:17632055 |
| Sabatini DM et al. | RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. | 1994 | Cell | pmid:7518356 |
| Schreiber SL | Immunophilin-sensitive protein phosphatase action in cell signaling pathways. | 1992 | Cell | pmid:1379518 |
| Crabtree GR | Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. | 1999 | Cell | pmid:10089876 |
| Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
| Griffith JP et al. | X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. | 1995 | Cell | pmid:7543369 |
| Milan D et al. | The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. | 1994 | Cell | pmid:7525078 |
| Chung J et al. | Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. | 1992 | Cell | pmid:1377606 |
| McKeon F | When worlds collide: immunosuppressants meet protein phosphatases. | 1991 | Cell | pmid:1716181 |
| Liu J et al. | Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. | 1991 | Cell | pmid:1715244 |
| Cameron AM et al. | Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. | 1995 | Cell | pmid:8521476 |
| Hemenway CS and Heitman J | Calcineurin. Structure, function, and inhibition. | 1999 | Cell Biochem. Biophys. | pmid:10099825 |
| Gu L et al. | A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. | 2015 | Cell Biochem. Biophys. | pmid:25287673 |
| Rucha A and Verspohl EJ | Heterologous desensitization of insulin secretion by GIP (glucose-dependent insulinotropic peptide) in INS-1 cells: the significance of Galphai2 and investigations on the mechanism involved. | 2005 May-Jun | Cell Biochem. Funct. | pmid:15376236 |
| Gold BG | Re: Jin E and Santo M "Neurite outgrowth of NG08-15 cells induced by heat shock protein 90 inhibitors". | 2008 | Cell Biochem. Funct. | pmid:18720425 |
| Tang L et al. | FK506 enhanced osteoblastic differentiation in mesenchymal cells. | 2002 | Cell Biol. Int. | pmid:11779223 |
| Lee WS et al. | Tacrolimus regulates endoplasmic reticulum stress-mediated osteoclastogenesis and inflammation: In vitro and collagen-induced arthritis mouse model. | 2018 | Cell Biol. Int. | pmid:28833755 |
| Gabryel B and Bernacki J | Effect of FK506 and cyclosporine A on the expression of BDNF, tyrosine kinase B and p75 neurotrophin receptors in astrocytes exposed to simulated ischemia in vitro. | 2009 | Cell Biol. Int. | pmid:19393753 |
| PalacÃn M et al. | FK506 affects mitochondrial protein synthesis and oxygen consumption in human cells. | 2013 | Cell Biol. Toxicol. | pmid:24077807 |
| Takadera T et al. | Cyclosporine A- and FK506-induced apoptosis in PC12 cells. | 2007 | Cell Biol. Toxicol. | pmid:17385075 |
| MacMillan D et al. | FK506-binding protein (FKBP12) regulates ryanodine receptor-evoked Ca2+ release in colonic but not aortic smooth muscle. | 2008 | Cell Calcium | pmid:17950843 |
| Zheng YM et al. | Role of FKBP12.6 in hypoxia- and norepinephrine-induced Ca2+ release and contraction in pulmonary artery myocytes. | 2004 | Cell Calcium | pmid:15036951 |
| Bultynck G et al. | Washing out of lipophilic compounds induces a transient increase in the passive Ca(2+) leak in permeabilized A7r5 cells. | 2002 | Cell Calcium | pmid:12098225 |
| Bielefeldt K et al. | Tacrolimus (FK506) modulates calcium release and contractility of intestinal smooth muscle. | 1997 | Cell Calcium | pmid:9502200 |
| Zheng J et al. | Ca(2+) release induced by cADP-ribose is mediated by FKBP12.6 proteins in mouse bladder smooth muscle. | 2010 | Cell Calcium | pmid:20451249 |
| Tamareille S et al. | High glucose-induced apoptosis through store-operated calcium entry and calcineurin in human umbilical vein endothelial cells. | 2006 | Cell Calcium | pmid:16243395 |
| Reyes RC et al. | Immunophilin deficiency augments Ca2+-dependent glutamate release from mouse cortical astrocytes. | 2011 | Cell Calcium | pmid:21163525 |
| Avila G and Dirksen RT | Rapamycin and FK506 reduce skeletal muscle voltage sensor expression and function. | 2005 | Cell Calcium | pmid:15955561 |
| Gibon J et al. | Store-depletion and hyperforin activate distinct types of Ca(2+)-conducting channels in cortical neurons. | 2010 | Cell Calcium | pmid:20621761 |
| Turner JD et al. | Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells. | 2009 | Cell Calcium | pmid:19758695 |
| Mayrleitner M et al. | The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. | 1994 | Cell Calcium | pmid:7511990 |
| Lombardi A et al. | Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. | 2017 | Cell Commun. Signal | pmid:29132395 |
| Cheng S and Rodier F | Manipulating senescence in health and disease: emerging tools. | 2015 | Cell Cycle | pmid:25928330 |
| Werneck MB et al. | Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. | 2012 | Cell Cycle | pmid:22992618 |
| Meller R et al. | Seizure-like activity leads to the release of BAD from 14-3-3 protein and cell death in hippocampal neurons in vitro. | 2003 | Cell Death Differ. | pmid:12728252 |
| Lim SW et al. | Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. | 2017 | Cell Death Dis | pmid:28771227 |
| Que J et al. | Effect of FK506 in reducing scar formation by inducing fibroblast apoptosis after sciatic nerve injury in rats. | 2013 | Cell Death Dis | pmid:23470533 |
| Bassing CH et al. | FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes. | 1998 | Cell Growth Differ. | pmid:9543388 |
| Barten MJ et al. | Pharmacodynamics of T-cell function for monitoring immunosuppression. | 2007 | Cell Prolif. | pmid:17227295 |
| Azzi J et al. | Targeted Delivery of Immunomodulators to Lymph Nodes. | 2016 | Cell Rep | pmid:27134176 |